ImmunityBio Q4 2024 Earnings Report
Key Takeaways
ImmunityBio reported a net product revenue of $7.2 million for Q4 2024, a 21% increase over the previous quarter. The company saw increased sales momentum after receiving a permanent J-code in January 2025 and has multiple milestones achieved.
Net product revenue for Q4 2024 reached $7.2 million, a 21% increase quarter-over-quarter.
ANKTIVA unit sales volume grew 97% in February 2025 compared to December 2024, following the permanent J-code issuance.
FDA authorized expanded access of an alternative source of BCG to address the BCG shortage.
Global submission of marketing authorization applications for ANKTIVA in combination with BCG was accepted for review by MHRA and EMA.
ImmunityBio
ImmunityBio
ImmunityBio Revenue by Segment
Forward Guidance
ImmunityBio anticipates continued growth and execution on its plans for the year, driven by recent milestones and approvals.
Positive Outlook
- Approval of ANKTIVA and the permanent J-code.
- Adoption of ANKTIVA by urologists for BCG unresponsive non-muscle invasive bladder cancer CIS.
- Authorization of expanded access of recombinant BCG to address the TICE BCG shortage.
- Acceptance of global marketing submission to EMA and MHRA.
- Potentially transformative RMAT designation by the FDA of ANKTIVA + PD-L1 t-haNK for the reversal of lymphopenia.
Challenges Ahead
- Potential delays in product availability and regulatory approvals.
- Risks associated with third-party collaborations and agreements.
- Potential product shortages or manufacturing disruptions.
- Challenges in scaling manufacturing and commercial supply operations.
- Risks in obtaining, maintaining, and enforcing patent protection.